| December 14th, 2019
Last week, Biogen announced that its Alzheimer’s drug aducanumab was effective in combating Alzheimer’s disease after all, and that it would be reviving a trial cancelled earlier this year. However, questions still remain about what’s next for patients and doctors as the drug moves toward FDA approval.
Dr. Sharon Cohen, Medical Director and Principal Investigator at the Toronto Memory Program, shares her views on Biogen’s revived trial and the potential behind aducanumab.
If you find our articles and interviews helpful, please consider becoming a supporting member of our community.
Frustrated by the lack of an editorially independent source of information on brain health and Alzheimer’s disease, we decided to create Being Patient.
We are a team of dedicated journalists covering the latest research on Alzheimer’s, bringing you access to the experts and elevating the patient perspective on what it’s like to live with dementia.
Please help support our mission.